Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore.
Jerry Zeng Yang WongJia Hui ChaiYen Shing YeohNur Khaliesah Mohamed RizaJenny LiuYik-Ying TeoHwee Lin WeeMikael HartmanPublished in: BMC health services research (2021)
Results from this cost-effectiveness analysis show that polygenic risk-tailored screening is cost effective with an ICER of - 3713.80 SGD/QALY. Tailored screening remains cost effective even across varying percentile cutoffs for each risk group. While the results look promising for incorporating polygenic risk into the current breast cancer screening programme, further studies should be conducted to address various limitations.
Keyphrases